中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 2
Mar.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(2): 318-325

Efficacy and safety of rifaximin in the prevention of spontaneous bacterial peritonitis: A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2021.02.015

  • Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China

  • Received Date: 2020-08-02
  • Accepted Date: 2020-08-25
  • Published Date: 2021-02-20
    Abstract
  •   Objective  To evaluate the efficacy and safety of rifaximin in the prevention of spontaneous bacterial peritonitis (SBP).  Methods  CNKI, Wanfang Data, CBM, PubMed, Embase, and Cochrane Library were searched for randomized controlled trials (RCTs) and cohort studies on rifaximin in the prevention of SBP published up to July 5, 2020. The articles were screened according to the inclusion and exclusion criteria, and data extraction and quality assessment were performed. RevMan 5.3 software was used to conduct the meta-analysis.  Results  A total of 13 studies (with 2207 patients in total) were included, among which there were 6 RCTs and 7 cohort studies. The results of the meta-analysis showed that compared with the non-prevention group, the rifaximin group had significantly lower incidence rate of SBP (odds ratio [OR]=0.36, 95% confidence interval [CI]: 0.14-0.96, P=0.04) and mortality rate (OR=0.59, 95% CI: 0.37-0.95, P=0.03); compared with the norfloxacin group, the rifaximin group had significantly lower incidence rate of SBP (OR=0.39, 95% CI: 0.25-0.62, P < 0.001), mortality rate (OR=0.55, 95% CI: 0.34-0.92, P=0.02), and adverse reactions (OR=0.36, 95% CI: 0.22-0.59, P < 0.001). The subgroup analysis based on the type of prevention showed that there was no significant difference in primary prevention between the two groups (OR=0.56, 95% CI: 0.23-1.35, P=0.20), and in secondary prevention, the rifaximin group had a significantly lower incidence rate of SBP (OR=0.18, 95% CI: 0.08-0.43, P < 0.001). In addition, it was also found that rifaximin significantly reduced the incidence rate of hepatorenal syndrome (OR=0.34, 95% CI: 0.15-0.77, P=0.01) and hepatic encephalopathy (OR=0.55, 95% CI: 0.32-0.95, P=0.03).  Conclusion  Rifaximin is safe and effective for the primary and secondary prevention of SBP. Rifaximin is superior to norfloxacin in secondary prevention, which still needs to be confirmed by high-quality multicenter RCTs.

     

    • FullText(HTML)
  • loading
    • References(29)
  • [1]
    DEVER JB, SHEIKH MY. Review article: Spontaneous bacterial peritonitis-bacteriology, diagnosis, treatment, risk factors and prevention[J]. Aliment Pharmacol Ther, 2015, 41(11): 1116-1131. DOI: 10.1111/apt.13172
    [2]
    FERNANDEZ J, NAVASA M, PLANAS R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis[J]. Gastroenterology, 2007, 133(3): 818-824. DOI: 10.1053/j.gastro.2007.06.065
    [3]
    European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J]. J Hepatol, 2010, 53(3): 397-417. DOI: 10.1016/j.jhep.2010.05.004
    [4]
    TANDON P, DELISLE A, TOPAL JE, et al. High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center[J]. Clin Gastroenterol Hepatol, 2012, 10(11): 1291-1298. DOI: 10.1016/j.cgh.2012.08.017
    [5]
    GOEL A, RAHIM U, NGUYEN LH, et al. Systematic review with meta-analysis: Rifaximin for the prophylaxis of spontaneous bacterial peritonitis[J]. Aliment Pharmacol Ther, 2017, 46(11): 1029-1036.
    [6]
    MARCIANO S, DIRCHWOLF M, DIAZ JM, et al. Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin[J]. Eur J Gastroenterol Hepatol, 2019, 31(4): 540-546. DOI: 10.1097/MEG.0000000000001331
    [7]
    OLIVER A, WONG M, SANCHEZ C. Role of rifaximin in spontaneous bacterial peritonitis prevention[J]. South Med J, 2018, 111(11): 660-665. DOI: 10.14423/SMJ.0000000000000887
    [8]
    ELFERT A, ABO ALIL, SOLIMAN S, et al. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis[J]. Eur J Gastroenterol Hepatol, 2016, 28(12): 1450-1454. DOI: 10.1097/MEG.0000000000000724
    [9]
    ASSEM M, ELSABAAWY M, ABDELRASHED M, et al. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: A prospective randomized open-label comparative multicenter study[J]. Hepatol Int, 2016, 10(2): 377-385. DOI: 10.1007/s12072-015-9688-z
    [10]
    MOSTAFA T, BADRA G, ABDALLAH M. The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients[J]. Turk J Gastroenterol, 2015, 26(2): 163-169. DOI: 10.5152/tjg.2015.7782
    [11]
    PRAHARAJ D, TANEJA S, DUSEJA A, et al. Randomized control trial of rifaximin and norfloxacin in primary and secondary prophylaxis of spontaneous bacterial peritonitis (SBP) in cirrhotic patients[J]. J Clin Exp Hepatol, 2017, 7(S2): s71.
    [12]
    SHAMSEYA MM, MADKOUR MA. Rifaximin: A reasonable alternative for norfloxacin in the prevention of spontaneous bacterial peritonitis in patients with HCV-related liver cirrhosis[J]. Alex J Med, 2015, 52(3): 219-226.
    [13]
    KUMAR A, SHAIKH BA, SHAIKH ZA, et al. Effectiveness of rifaximin versus norfloxacin in prevention of spontaneous bacterial peritonitis in cirrhotic patients[J]. Med Forum, 2019, 30(8): 90-94.
    [14]
    FLAMM SL, MULLEN KD, HEIMANSON Z, et al. Rifaximin has the potential to prevent complications of cirrhosis[J]. Therap Adv Gastroenterol, 2018, 11: 1-10.
    [15]
    HANOUNEH MA, HANOUNEH IA, HASHASH JG, et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis[J]. J Clin Gastroenterol, 2012, 46(8): 709-715. DOI: 10.1097/MCG.0b013e3182506dbb
    [16]
    LUTZ P, PARCINA M, BEKEREDJIAN-DING I, et al. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites[J]. PLoS One, 2014, 9(4): e93909. DOI: 10.1371/journal.pone.0093909
    [17]
    VLACHOGIANNAKOS J, VIAZIS N, VASIANOPOULOU P, et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis[J]. J Gastroenterol Hepatol, 2013, 28(3): 450-455. DOI: 10.1111/jgh.12070
    [18]
    SHOKOOHI S, ZIVONY A, LE D, et al. Rifaximin is associated with decreased incidence of spontaneous bacterial peritonitis in cirrhotics with ascites[J]. Hepatology, 2013, 58(s1): 858a.
    [19]
    DONG T, ARONSOHN A, REDDY KG, et al. Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis[J]. Dig Dis Sci, 2016, 61(12): 3621-3626. DOI: 10.1007/s10620-016-4313-0
    [20]
    DANULESCU RM, CIOBICA A, STANCIU C, et al. The role of rifaximine in the prevention of the spontaneous bacterial peritonitis[J]. Rev Med Chir Soc Med Nat Iasi, 2013, 117(2): 315-320.
    [21]
    MENSHAHAWY A, MATTAR O, BARSSOUM K, et al. Safety and efficacy of rifaximin in prophylaxis of spontaneous bacterial peritonitis: A systematic review and Meta-analysis[J]. Curr Drug Targets, 2019, 20(4): 380-387. DOI: 10.2174/1389450119666180924145156
    [22]
    SIDHU GS, GO A, ATTAR BM, et al. Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: A systematic review[J]. BMJ Open Gastroenterol, 2017, 4(1): e000154. DOI: 10.1136/bmjgast-2017-000154
    [23]
    FIORE M, MARAOLO AE, GENTILE I, et al. Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis[J]. World J Hepatol, 2017, 9(30): 1166-1175. DOI: 10.4254/wjh.v9.i30.1166
    [24]
    SALEHI S, TRANAH TH, LIM S, et al. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list[J]. Aliment Pharmacol Ther, 2019, 50(4): 435-441. DOI: 10.1111/apt.15326
    [25]
    KAMAL F, KHAN MA, KHAN Z, et al. Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis[J]. Eur J Gastroenterol Hepatol, 2017, 29(10): 1109-1117. DOI: 10.1097/MEG.0000000000000940
    [26]
    NAVASA M, FOLLO A, FILELLA X, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: Relationship with the development of renal impairment and mortality[J]. Hepatology, 1998, 27(5): 1227-1232. DOI: 10.1002/hep.510270507
    [27]
    BAJAJ JS. Review article: Potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis[J]. Aliment Pharmacol Ther, 2016, 43(S1): 11-26.
    [28]
    KIMER N, KRAG A, MOLLER S, et al. Systematic review with meta-analysis: The effects of rifaximin in hepatic encephalopathy[J]. Aliment Pharmacol Ther, 2014, 40(2): 123-132. DOI: 10.1111/apt.12803
    [29]
    LYU XY, LI L. ClinicaI effect of rifaximin in treatment of complications associated with Iiver cirrhosis[J]. J Clin Hepatol, 2018, 34(7): 1551-1554.(in Chinese) DOI: 10.3969/j.issn.1001-5256.2018.07.040

    吕新月, 李磊. 利福昔明在肝硬化相关并发症中的应用[J]. 临床肝胆病杂志, 2018, 34(7): 1551-1554. DOI: 10.3969/j.issn.1001-5256.2018.07.040
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(8)  / Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (669) PDF downloads(73) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return